SOLICITATION NOTICE
A -- Drug Formulation and Manufacturing Contract
- Notice Date
- 7/24/2018
- Notice Type
- Synopsis
- NAICS
- 325412
— Pharmaceutical Preparation Manufacturing
- Contracting Office
- 6011 Executive Blvd 5th Floor Rockville MD 20852-3804
- ZIP Code
- 20852-3804
- Solicitation Number
- NIHOD201800029
- Point of Contact
- Robert Burdette, Contract Specialist
- E-Mail Address
-
CMSSDA@od.nih.gov
- Small Business Set-Aside
- Partial Small Business
- Description
- PRE-SOLICITATION NOTICE Pursuant to FAR subpart 5.2, "Synopsis of Proposed Contract Actions", this is a pre-solicitation notice of a proposed contract Action. Acquisition Authority: This acquisition is being conducted under Federal Acquisition Regulations (FAR) 15, Contracting by Negotiation. North American Classification System (NAICS) Code: The intended procurement is classified under NAICS code 325412 -- Pharmaceutical Preparation Manufacturing with a size standard of 1,250 employees. Set-Aside Status: This acquisition is intended to be a partial small business set-aside. Additional information will be provided with the solicitation release. This information will not be provided to individual vendors prior to the solicitation release. Description of Requirement: The NIH Clinical Center (CC), Pharmacy Department, Investigational Drug Management and Research Service (IDMRS); the Office of Research Support and Compliance (ORSC); and the Office of Logistics and Acquisition Operations (OLAO) are partnering to establish a suite of multiple award Indefinite Delivery/Indefinite Quantity (ID/IQ) contracts that, together, will constitute the Drug Formulation and Manufacturing Contracts (DFMC). The DFMC will allow NIH ICs to hire contractors to conduct the development and manufacture of dosage forms of small molecule drug candidates suitable for administration in preclinical efficacy studies, Investigational New Drug (IND) enabling studies, and clinical trials. The goal of the contracts is to complete all the manufacturing, documentation, formulation, fill and finish, packaging, and labeling required for investigational drug compounds. Throughout the period of performance of the contract, the contractor must maintain the technical capabilities, minimum resources and organizational compliances with which to successfully conduct any awarded contract activity. Additionally, unless otherwise requested any assigned research must be performed in compliance with, all current FDA, World Health Organization (WHO), and International Committee on Harmonization (ICH) policies, practices, procedures, guidelines and regulations specific to current good manufacturing practices (cGMP) as may be applicable. Period of Performance: These contracts will include a two-year base period and three one-year option periods. NOTE: THIS NOTICE MAY HAVE POSTED ON FEDBIZOPPS ON THE DATE INDICATED IN THE NOTICE ITSELF (24-JUL-2018). IT ACTUALLY APPEARED OR REAPPEARED ON THE FEDBIZOPPS SYSTEM ON 21-DEC-2018, BUT REAPPEARED IN THE FTP FEED FOR THIS POSTING DATE. PLEASE CONTACT 877-472-3779 or fbo.support@gsa.gov REGARDING THIS ISSUE.
- Web Link
-
Link To Document
(https://www.fbo.gov/spg/HHS/NIH/OoA/NIHOD201800029/listing.html)
- Place of Performance
- Address: Contractor and NIH Facilities
- Country: US
- Country: US
- Record
- SN05180817-F 20181223/181221230011 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |